Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,353.50 GBX | +0.48% | -1.24% | -6.67% |
07:51pm | European Equities Close Higher in Thursday Trading; EU GDP Rises in Q3 | MT |
01:12pm | GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment | MT |
Summary: GSK plc
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: GSK plc
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: GSK plc
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings Chart: GSK plc
ESG chart: GSK plc
Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
---|---|---|---|---|---|
70.69B | |||||
731B | |||||
475B | |||||
369B | |||||
301B | |||||
249B | |||||
240B | |||||
208B | |||||
200B | |||||
162B | |||||
Average | 300.57B | ||||
Weighted average by Cap. |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GSK Stock
- Ratings GSK plc